{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Blanco-Blazquez V"],"funding":["ISCIII","Instituto de Salud Carlos III","European Union","Junta de Extremadura, Consejeria de Economía e Infraestructuras","Agencia Estatal de Investigación","Junta de Extremadura, Consejería de Economía, Ciencia y Agenda Digital"],"pagination":["86"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9960949"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(2)"],"pubmed_abstract":["Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administration of HGF-loaded extended release microspheres in an acute myocardial infarction (AMI) swine model. An IC infusion of 5 × 10<sup>6</sup> HGF-loaded microspheres (MS+HGF, <i>n</i> = 7), 5 × 10<sup>6</sup> placebo microspheres (MS, <i>n</i> = 7), or saline (SAL, <i>n</i> = 7) was performed two days after AMI. TIMI flow and Troponin I (TnI) values were assessed pre- and post-treatment. Cardiac function was evaluated with magnetic resonance imaging (cMR) before injection and at 10 weeks. Plasma c"],"journal":["Journal of cardiovascular development and disease"],"pubmed_title":["Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model."],"pmcid":["PMC9960949"],"funding_grant_id":["PID2019-107329RAC22/AEI/10.13039/501100011033","PI20/00247","GR21201","GR18199","IB20191"],"pubmed_authors":["Martin H","Palacios I","Gonzalez-Bueno I","Blazquez R","Crisostomo V","Solares J","Casado JG","Steendam R","Blanco-Blazquez V","Baez-Diaz C","Uson A","Sanchez-Margallo FM"],"additional_accession":[]},"is_claimable":false,"name":"Intracoronary Administration of Microencapsulated HGF in a Reperfused Myocardial Infarction Swine Model.","description":"Therapy microencapsulation allows minimally invasive, safe, and effective administration. Hepatocyte growth factor (HGF) has angiogenic, anti-inflammatory, anti-apoptotic, and anti-fibrotic properties. Our objective was to evaluate the cardiac safety and effectiveness of intracoronary (IC) administration of HGF-loaded extended release microspheres in an acute myocardial infarction (AMI) swine model. An IC infusion of 5 × 10<sup>6</sup> HGF-loaded microspheres (MS+HGF, <i>n</i> = 7), 5 × 10<sup>6</sup> placebo microspheres (MS, <i>n</i> = 7), or saline (SAL, <i>n</i> = 7) was performed two days after AMI. TIMI flow and Troponin I (TnI) values were assessed pre- and post-treatment. Cardiac function was evaluated with magnetic resonance imaging (cMR) before injection and at 10 weeks. Plasma c","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2026-04-07T13:24:00.87Z","creation":"2025-04-07T00:31:59.199Z"},"accession":"S-EPMC9960949","cross_references":{"pubmed":["36826582"],"doi":["10.3390/jcdd10020086"]}}